Upper Airway Stimulation versus Untreated Comparators in Positive Airway Pressure Treatment-Refractory Obstructive...

Area of Science:

• Sleep Medicine
• Medical Devices
• Health Policy

Background:

• Obstructive sleep apnea (OSA) significantly impacts patient health and quality of life.
• Upper airway stimulation (UAS) offers a treatment alternative for OSA patients.
• Insurance coverage is a critical factor influencing patient access to UAS therapy.

Purpose of the Study:

• To evaluate the impact of insurance coverage on OSA outcomes in patients seeking UAS.
• To compare the natural history of OSA outcomes between patients receiving UAS and those denied insurance coverage.

Main Methods:

• A multinational prospective study (NCT02907398) employed a parallel-arm design.
• Objective sleep apnea measures (e.g., apnea-hypopnea index) and patient-reported outcomes were compared.
• Statistical analyses included Wilcoxon rank-sum tests and logistic regression.

Main Results:

• Patients receiving UAS showed a significantly greater reduction in apnea-hypopnea index (-19.1 vs. -8.1, P < 0.001) and improved nocturnal hypoxia.
• Subjective improvements in dozing propensity (Epworth Score: -5.1 vs. 1.8, P < 0.001) and overall sleep quality were greater with UAS.
• Lower odds of insurance approval were observed for women (OR, 0.40) and prior oral appliance users (OR, 0.35).

Conclusions:

• Upper airway stimulation leads to significant improvements in both objective and subjective sleep apnea burden.
• Findings emphasize the need for optimized care pathways for patients denied UAS and policy initiatives to address insurance-related disparities.
• Sex-specific disparities in insurance approval warrant further investigation and intervention.